Description

Key Features:

• CJC-1295 with DAC is a modified long-acting form of a GHRH analogue.
• It is studied for extended receptor interaction and peptide stability.
• Its pharmacokinetic profile is of interest in endocrine research.

Description:

The Drug Affinity Complex (DAC) modification allows extended binding to plasma proteins, resulting in prolonged activity in research models. Studies focus on sustained growth hormone signaling, endocrine feedback regulation, and peptide half-life extension mechanisms.

Research Use Only: This product is intended exclusively for laboratory and scientific research. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.